Leerink: 'CIRRUS Part D data continue to look supportive of EDG-7500’s potential'

June 16, 2026 8:55 AM

Leerink analyst Joseph Schwartz reiterated an Outperform rating and $50.00 price target on Edgewise Therapeutics (NASDAQ: EWTX)The analyst comments "CIRRUS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found